January 2024

pCR rates improve regardless of whether patients received full chemotherapy doses.

Trastuzumab deruxtecan and elacestrant represent important new treatment options.

No established standard of care currently exists after spread to the lymph nodes.

The combination resulted in numerically longer OS compared with an NSAI alone.

The MRD-guided treatment approach has a significant advantage over chemotherapy.

It can also help identify patients who would benefit from disease-specific therapies.

Data support the quadruplet regimen as a new standard of care for transplant-eligible patients.

There is a significant efficacy-effectiveness gap in standard-of-care regimens.

Further policy changes to promote gender equity may be needed.

Ph-like ALL may be predominantly prevalent in Hispanic and Latino populations.

Significant study results could inform clinical practice strategies.

Presentations detail clinical trial results and focus on drugs in the pipeline.

2023 was an impactful year for the field of oncology pharmacy.